Enoticumab Biosimilar - Research Grade

Human

DLL4

>1mg/ml

IgG1 - kappa

CHO Cells

Anti-Mouse DLL4 (HMD4-2) In Vivo Antibody - Low Endotoxin (ICH1269), Demcizumab Biosimilar - Research Grade (ICH5472)

https://www.imgt.org/mAb-DB/

ICH3002

Q9NR61

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of enoticumab, supplied for research use only. It is a fully human IgG1-kappa antibody built around Delta-like ligand 4 (DLL4), the Notch pathway ligand targeted by the originator molecule. It is not the clinical drug and is not intended for human or veterinary use. The analog reproduces the binding specificity of the parent antibody, making it a practical tool for laboratory work: as a positive control in DLL4 binding and blocking assays, as a reference reagent when benchmarking novel anti-DLL4 antibodies or bispecifics, as a starting point for antibody-drug conjugate or ADCC/CDC assay development, and for target-engagement studies in cell-based systems. Supplied unconjugated so users can label or reformat as needed. Available at research-grade low endotoxin (<1 EU/mg) and ultra-low endotoxin (<0.5 EU/mg) grades, and in bulk milligram-to-gram quantities for larger screening campaigns and preclinical model work. Because it is a research analog rather than the formulated therapeutic, buffer, concentration and endotoxin can be matched to assay requirements. Delta-like ligand 4 (DLL4; UniProt Q9NR61) is a single-pass transmembrane ligand of the Notch signaling pathway, expressed predominantly by arterial and tip endothelial cells. Binding of DLL4 to Notch1/Notch4 receptors on neighboring cells triggers receptor cleavage and release of the Notch intracellular domain, which drives transcription of downstream genes. In the vasculature, DLL4-Notch signaling is a central regulator of sprouting angiogenesis: it restrains excessive tip-cell formation and vessel branching, thereby promoting the formation of functional, well-perfused vasculature. Paradoxically, blocking DLL4 increases vessel sprouting but yields non-productive, poorly perfused networks, an effect exploited in oncology research. DLL4 also contributes to arterial specification and to immune and stem-cell regulation. Its dysregulation is implicated in tumor angiogenesis, making it an actively studied target.

Drosophila Delta homolog 4, Delta4, Delta-like protein 4

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Enoticumab biosimilar available in bulk or gram quantities?

A: Yes — the Enoticumab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Enoticumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Enoticumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Enoticumab that binds DLL4.